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Abbreviations used
AD: Atopic dermatitis
DM: Double mutant
FLG: Filaggrin
HDM: House dust mite
hpf: High-power field
MAPEG: Membrane-associated proteins in eicosanoid and
glutathione metabolism
OR: Odds ratio
SNP: Single nucleotide polymorphism
TEWL: Transepidermal water loss
WT: Wild-type
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1122 SAUNDERS ET ALMethods: A mouse genetics approach was used to separate the
matted and Flg mutations to produce congenic single-mutant
strains for genetic and immunologic analysis. Next-generation
sequencing was used to identify the matted gene. Five
independently recruited AD case collections were analyzed to
define associations between single nucleotide polymorphisms
(SNPs) in the human gene and AD.
Results: The matted phenotype in flaky tail mice is due to a
mutation in the Tmem79/Matt gene, with no expression of the
encoded protein mattrin in the skin of mutant mice.Mattft mice
spontaneously have dermatitis and atopy caused by a defective
skin barrier, with mutant mice having systemic sensitization after
cutaneous challenge with house dust mite allergens. Meta-analysis
of 4,245 AD cases and 10,558 population-matched control subjects
showed that a missense SNP, rs6694514, in the humanMATT gene
has a small but significant association with AD.
Conclusion: In mice mutations in Matt cause a defective skin
barrier and spontaneous dermatitis and atopy. A common SNP
in MATT has an association with AD in human subjects.
(J Allergy Clin Immunol 2013;132:1121-9.)
Key words: Allergy, association, atopic dermatitis, atopy, eczema,
filaggrin, flaky tail, Matt, mattrin, mouse, mutation, Tmem79
Atopic dermatitis (AD) is the most common diagnosis in
dermatology, affecting approximately 1 in 5 children in the
developed world,1 and is frequently associated with atopic asthma
and a wide range of allergies.2 AD is a highly heritable complex
trait; however, environmental influences also play a role in trig-
gering the atopic diathesis.3 Genome-wide association studies in
ADhave identified several susceptibility loci4-7; however, themajor
and only functionally characterized genetic factor is the filaggrin
gene (FLG), which encodes the skin barrier protein filaggrin.3 Prev-
alent loss-of-function variants in FLG were identified as the cause
of the single-gene disorder ichthyosis vulgaris (dry flaky skin).8
Soon thereafter, these variantswere shown to be strongly associated
with AD,9 with heterozygous odds ratios (ORs) of greater than 7
and homozygous ORs of greater than 150 in case-control studies
in which both prevalent and rare variants were analyzed.10
The hypothesis that skin barrier deficiency in the context ofFLG
mutations is an initiator of AD was confirmed experimentally by
using the flaky tail mouse mutant,11 which was shown to carry a
frameshift mutation in the murine Flg gene.12 Flaky tail mice
have a defective skin barrier, with increased percutaneous transfer
of antigens and chemical haptens.12-15 The ftmutation arose spon-
taneously in 1958 in the progeny of crosses between heterogeneous
stocks of mice with the recessive mutation matted (ma), and these
mutations aremaintained as a double-mutant (DM) strain known as
maft. The matted hair phenotype was used for many years as a sur-
rogatemarker for the ftmutation because, remarkably, the ft andma
mutations are closely linked on chromosome 3 in the mouse.16 The
DMmaftmice have been routinely used for studies of skin barrier–
deficient AD in recent years.13-15,17 Inmice and human subjects the
FLG gene resides in the epidermal differentiation complex, a clus-
ter ofmore than 70 genes encoding proteins involved in skin barrier
formation and differentiation of stratified epithelia,18 including
those within the hair follicle.18-21 We suspected the nearby ma
gene might also be involved in epithelial barrier function, and in
this study we set out to separate this allele from Flgft and identify
the causative defect.METHODS
Isolation of the matted mouse strain
DMMattma/maFlgft/ft mice were provided by Dr John P. Sundberg (Jackson
Laboratory, Bar Harbor, Me).12 DMmicewere crossed with C57BL/6Jmice to
generateMattma/1Flgft/1mice. The Flgft andMattmamutations were separated
and backcrossed to congenic C57BL/6J background in accordance with the
breeding strategy outlined (see Fig E1 in this article’s Online Repository at
www.jacionline.org). C57BL/6J micewere used as wild-type (WT) control an-
imals. B6.CBAGr-ma/J (JAXMattma/ma) mice were obtained from the Jackson
Laboratory. Mice were housed in specific pathogen-free conditions, with irra-
diated diet and bedding and water ad libitum. All animal experiments were per-
formed in compliancewith IrishDepartment ofHealth andChildren regulations
and approved byTrinityCollegeDublin’s BioResources Ethical ReviewBoard.Gene mapping
Skin sampleswere obtained fromneonatalmice, andDNAwas extracted by
using the DNA Purification Kit (Promega, Madison, Wis). Genomic DNA
extracted from murine neonatal blood was amplified with the GoTaq Flexi
DNA Polymerase kit (Promega). All samples were sequenced by using the
ABI 3730 DNA Systems (Applied Biosystems, Foster City, Calif). Mapping
primers were used to amplify and sequence murine chromosome 3 (see Table
E1, A, in this article’s Online Repository at www.jacionline.org). Matted
genomic sequences were comparedwith C57BL/6J for regions of congenicity.Next-generation sequencing and bioinformatics
Three replicates from each sample (WTandMattma/ma) were submitted for
next-generation sequencing. The replicates were run multiplexed on an Illu-
mina GAIIx and HiSeq 2000 (Illumina, San Diego, Calif) by using v3
sequencing chemistry and the Roche 454 Titanium workflow (Roche, Man-
nheim, Germany). For further details on sequencing, bioinformatics, and sin-
gle nucleotide polymorphism (SNP) and InDel methodologies, see the
Methods section in this article’s Online Repository at www.jacionline.org.Analysis and identification of murine Tmem79/Matt
gene
Each of the 4 exons was amplified individually by using PCR with the
following conditions for all exons: 1 cycle of 948C for 5 minutes; 35 cycles of
948C for 30 seconds, 548C for 30 seconds, and 728C for 1 minute; and a final
extension at 728C for 5 minutes.
Semiquantitative RT-PCR
Mouse tissue samples were lysed with TissueLyser LT (Qiagen, Hilden,
Germany), and RNA was extracted with the RNeasy kit (Qiagen). RNA was
reverse transcribed with the ImProm-II Reverse Transcription System
(Promega). An intron-spanning amplification was carried out on Tmem79/
Matt across exons 3 and 4. Krt14 was used as a loading control. RT-PCR
primers used are shown in Table E1, B, in this article’s Online Repository.
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The 644-bp PCR product of the third Tmem79/Matt exon was digested with
the restriction enzyme CviQI (New England Biolabs, Ipswich, Mass), and di-
gested fragments were separated on agarose gel by using electrophoresis.
Primers used are shown in Table E1, A. The Flgft mutation was genotyped,
as previously described.12
Immunoblotting
The epidermis was separated from the dermis of neonatal mice after
immersion in 5mmol/LEDTAat 508C for 5minutes, followed by cooling in ice-
cold PBS. The separated epidermis was extracted in urea/Tris buffer containing
protease inhibitor cocktail (Halt; Thermo Scientific, Erembodegem, Belguim)
by means of homogenization. Protein samples were separated on SDS-
polyacrylamide gels and transferred to polyvinylidene difluoride membranes
(Millipore, Temecula, Calif), which were probed with rabbit polyclonal
antibodies specific for human mattrin (TMEM79; Novus Biologicals, Littleton,
Colo). Primary antibodies were detected by means of incubation with a
horseradish peroxidase–conjugated goat anti-rabbit secondary antibody (Dako,
Stockport, United Kingdom). Immunolabeled proteins were visualized by using
chemiluminescence with the ECL detection system (Millipore).
Immunofluorescence and Nile Red staining
Dorsal murine sections were obtained from 4-day-old neonatal mice and
snap-frozen immediately. All frozen samples were then cryosectioned at 4 to 5
mm and stored at 808C until use. After drying, sections were fixed in 50%
methanol acetone, washed in PBS, and incubated with primary antibodies.
Nuclei were stained with 49-6-diamidino-2-phenylindole (Sigma-Aldrich, St
Louis, Mo), and slides were fixed in Hydromount (National Diagnostics,
Atlanta, Ga). Primary antibodies used in whole mounts were as follows:
polyclonal TMEM79 (TMEM79; Novus Biologicals) and monoclonal CK-13
against cytokeratin 17 (Sigma-Aldrich). Frozen mouse skin sections were
stainedwithNile Red and 6-diamidino-2-phenylindole. Imageswere collected
with a Zeiss LSM700 confocal microscope (Zeiss, Oberkochen, Germany).
Quantitative PCR of human cDNA tissue array
Expression of TMEM79/MATT cDNA was quantified across a multiple-
tissue panel containing cDNA from 48 different human tissues (Origene Tech-
nologies, Rockville, Md). This was done with the TaqMan Gene Expression
Assay, C_25986870_10 (Life Technologies, Carlsbad, Calif), which spans
exons 3 to 4 to result in amplicon length of 65 bp in cDNA sequence. The stan-
dard used in this assay was a commercially available plasmid containing the
full-length WT TMEM79/MATT (Origene Technologies). A standard curve
was calculated by using the formulae provided by Applied Biosystems.
Phenotypic scoring
The severity of inflammation and AD-like pathology was scored by using
themacroscopic diagnostic criteria described for the skin inflammation seen in
the Nc/Nga mouse model of AD.22 Briefly, a scoring system (0, none; 1, mild;
2, moderate; and 3, severe) was applied to the symptoms of pruritus, edema,
erosion, scaling, and erythema. Pruritus (scratch behavior) was observed for
5 minutes. Total scores for each mouse were calculated from the sum of indi-
vidual scores.
Cutaneous challenge with house dust mite antigen
Mice were challenged with house dust mite (HDM) to induce allergic skin
sensitization, as previously described.13 Briefly, HDM (Greer Laboratories,
Lenoir, NC) was topically applied to intact skin of WT and Mattma mice by
using Finn chamber patch tests (SmartPractice, Phoenix, Ariz) and secured
with Scanpor tape (Bio-Diagnostics, Worcester, United Kingdom). The
regimen involved five 1-week exposures to the allergen patch separated by
2-week intervals. Hair was clipped 24 hours before application of HDM that
was prepared in endotoxin-free Dulbecco PBS and vehicle to a concentration
of 1 mg/mL. Dulbecco PBS was used as the control. Mice were assessed 24
hours after the final HDM challenge.ELISA
Serum levels of HDM-specific IgE, IgG1, and IgG2a were detected by
means of direct ELISA. Total serum IgE levels were measured with a sand-
wich ELISA, according to the manufacturer’s instructions (BD PharMingen,
San Jose, Calif).
Histology
Dorsal skin sectionswere removed and fixed in 10% formal saline. Paraffin-
embedded sections were stained with hematoxylin and eosin and examined in
blinded fashion by 2 observers independently. To quantify dermal cell
numbers, we used a previously described scoring system.12 The total number
of cells per high-power field (hpf) of view were counted on 20 hpfs per mouse.
For skin sections, an arbitrary histologic scoring system was used to quantify
acanthosis and hyperkeratosis. Acanthosis scoring was based on the magni-
tude of epidermal hyperplasia, and hyperkeratosis scoring was based on the
magnitude of stratum corneum thickening, with scores (0, basal; 1, mild; 2,
moderate; 3, marked; 4, very marked; and 5, extreme pathology) for each
parameter based on measurements per hpf in sections.
Measurement of transepidermal water loss
A Courage and Khazaka Tewameter TM210 (Enviroderm, Evesham,
United Kingdom) was used for measurement of transepidermal water loss
(TEWL), which was measured on the dorsal flank of mice 24 hours after hair
clipping. TEWL was recorded at an ambient temperature of 198C to 218C and
humidity of 50%6 5%. In mice sensitized to HDM, TEWL was measured in
PBS- and HDM-treated mice before and after the HDM challenge regimen.
Electron microscopy
For scanning electron microscopy, hair fibers were removed frommice and
fixed in cacodylate-buffered glutaraldehyde. Samples were prepared for
scanning electron microscopy by using established procedures11 and exam-
ined in a Zeiss Supra scanning electron microscope.
Statistical analysis of mouse studies
GraphPad Prism software (GraphPad Software, La Jolla, Calif) was used
for data analysis. Differences between groups were determined by using the
Student t test and 2-way ANOVA. Results are presented as means 6 SEMs.
Differences, indicated as 2-tailed P values, were considered significant at a
P value of less than .05.
SNP identification in human subjects
Human samples from England, Scotland, and Ireland were obtained with
consent from patients and Institutional Ethics Committee approval complying
with the principles of the Declaration of Helsinki. HumanMATTwas sequenced
by using primers listed in Table E1, C, in this article’s Online Repository at
www.jacionline.org. Conditions for all exons except exon 2.2 were as follows:
1 cycle of 948C for 5minutes; 35 cycles of 948C for 30 seconds, 548C for 30 sec-
onds, and 728C for 1 minute; and a final extension at 728C for 5 minutes. An an-
nealing temperature of 588C was used for exon 2.2. SNP rs6684514 (see Table
E2 in this article’s Online Repository at www.jacionline.org) was genotyped
across the case-control study populations by using the TaqMan allelic discrim-
ination genotyping assay (C_25986870_10, Life Technologies Corporation).
Case-control studies
Five independently recruited AD case collections were compared with
ethnically matched population control subjects (see the Methods section in
this article’s Online Repository). Case definitions are described in the
Methods section in this article’s Online Repository, and demographic data
relating to these AD case collections and control subjects are summarized
in Table E3 in this article’s Online Repository at www.jacionline.org.
Genotype imputation
For in silico replication, we used the 2 German AD case-control selections
(see Table E3), which had been genotyped on Illumina 300k and Affymetrix
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1000 Genomes database (phase I integrated variant set release, March 2012).
Previous imputation data sets were curated, and samples with a greater than
5% missing rate, excess of heterozygosity (65 SDs away from the sample
mean), and unexpected relatedness (PI_HAT>0.1875, halfway between ex-
pected IBD for third- and second-degree relatives) were excluded. Further out-
liers from the multidimensional scaling of the pairwise IBS matrix were
removed. Imputation was carried out with SHAPEIT and IMPUTE2. The
SNP rs6684514 investigated in silico had an imputation quality of 0.996
(proper info) and a CR of 0.997.Statistical genetics
Case-control comparisons for each case collection and population control
subjects were performed by using logistic regression analysis in Stata 12.0
(StataCorp, College Station, Tex). Meta-analysis (under fixed- and random-
effects models) of the resulting log ORs and their SEs was performed with the
‘‘metan’’ function in Stata 12.0.RESULTS
Identification of Matt as the gene mutation in
matted mice
To separate the 2 mutations in the DM maft mice, we used the
backcross-intercross protocol outlined in Fig E1. Mice with the
Flgft mutant allele (Flg c.5303delA) were genotyped, as previ-
ously described.12 Progeny from putative heterozygous inter-
crosses were checked for the recessive matted hair phenotype to
identify ma/ma homozygotes. By this means, we separated both
alleles. Because SNP analysis showed that the initial DM maft
mouse was maintained on a mixed-strain background, we gener-
ated single-mutant N12 mice congenic on the C57BL/6J back-
ground. By using this backcross-intercross strategy to generate
congenic ma/ma homozygous mice (see Fig E1), the recessive
disease–causing locus should be ultimately visible as a small
area of homozygosity flanked by 2 unequal heterozygous regions
(see Fig E2, A, in this article’s Online Repository at www.
jacionline.org). To map this, we sequenced several short PCR
fragments across the region from C57BL/6J congenic ma/ma ho-
mozygotes (see Table E1, A) to identify SNPs. By this means, a
1.05-Mb critical interval was defined (Fig 1, A). In parallel, we
used epidermal transcriptomic sequencing to compare WT
C57BL/6J and congenic ma/ma homozygotes. A nonsense muta-
tion, p.Y280*, in the Tmem79 gene, located within the interval
(Fig 1, A), was identified in the RNAseq data (not shown). The
mutation in Tmem79 was confirmed by using conventional
sequencing of genomic PCR products (Fig 1,B) and restriction di-
gests (see Fig E2, B). This mutant transcript was expressed at
approximately 30% of the WT levels in ma/ma epidermis
(Fig 1, C). By using a commercially available antibody against
the C-terminus of the encoded protein, a single band of approxi-
mately 49 kDa was seen in epidermal extracts from WTand con-
genic Flgft/ftmice, with the protein absent in congenicma/ma and
DMmice (Fig 1,D), indicating the presence of a truncated protein
or an absence of protein in these mice. Interestingly, epidermal
extracts from Flgft/ft mice had increased expression of protein
relative to WT extracts. Tmem79 was renamed Matt, encoding
the protein mattrin; similarly, the human ortholog was renamed
MATT (approved by the Genome Nomenclature Committee).
By convention, after identification of the gene, the ma mutant
allele was redesignated as Mattma.Mattrin is expressed in mouse and human skin
Matt is a compact 5-exon gene on mouse 3qF1 spanning 5781
bp of genomic DNA, encoding a 391-amino-acid protein with a
calculated molecular weight of 43.5 kDa. The human ortholog,
MATT, which is syntenic on 1q23.1, has an identical organization.
Mattrin is a transmembrane domain protein with no previously
ascribed function (Fig 1, E). Bioinformatics analysis predicts a
long internal N-terminal domain, 5 transmembrane domains,
and a short C-terminus (Fig 1, E, and see Fig E3 in this article’s
Online Repository at www.jacionline.org). The mutation
p.Y280* occurs before the third transmembrane domain
(Fig 1, E). Immunohistochemistry revealed that mattrin was pre-
sent in epidermal granular layer keratinocytes in WT mice
(Fig 2, A) but was absent fromMattma/ma animals (Fig 2, B). Simi-
larly, the protein was observed in granular layer cells in human
epidermis (see Fig E4, A and B, in this article’s Online Repository
at www.jacionline.org) and was also found in the hair follicles of
mice (Fig 2,A) and human subjects (see Fig E4,C andD). In addi-
tion, the mRNA is widely expressed in human tissues and, consis-
tent with immunohistochemistry, is strongly expressed in skin
(see Fig E4, E).
Expression quantitative trait locus analysis23 showed thatMatt
is in a network of proteins expressed late in epidermal differenti-
ation, with an expression quantitative trait locus profile closely
matching that of Rhbg (transporter protein) and Rab25 (mem-
brane trafficking, data not shown). Mattrin shows distant
sequence homology to the Membrane-Associated Proteins in
Eicosanoid and Glutathione metabolism (MAPEG) protein fam-
ily (see Fig E3),24 members of which have roles in lipid catabo-
lism.25 Immunohistochemistry with the lipophilic dye Nile Red
revealed highly organized stacks of cornified cell envelopes in
the stratum corneum of WT animals (Fig 2, C) that were highly
disorganized in Mattma/ma mice, with discontinuous, uneven,
and highly disorganized cornified cell envelopes (Fig 2, D).Mattma/ma mice have spontaneous dermatitis
Gross examination of adult Flgft/ft andMattma/ma mice demon-
strates that the 2 strains differ considerably from each other (Fig 3,
A). Macroscopic clinical scoring22 demonstrated Mattma/ma and
DM mice spontaneously having progressive dermatitis-like skin
inflammation, which did not occur in adult Flgft/ft animals (see
Fig E5, A, in this article’s Online Repository at www.jacionline.
org). Although all Mattma/ma and DM mice had marked skin
inflammation, there was a broad spectrum of pathology, with
some animals exhibiting profound lesions and excoriation and oc-
casional blepharitis and eyelid dermatitis (see Fig E6, B, in this
article’s Online Repository at www.jacionline.org). Interestingly,
both neonatal Flgft/ft and DM mice have significant ichthyosis
(P < .001) compared with WT mice, but Mattma/ma mice did
not, indicating the postnatal importance of filaggrin (see Fig E5,
A, and E6, A).
With respect to the matted hair phenotype,11,26 bothMattma/ma
and DM animals had the keratinization defect, with hairs forming
clumps11,26 and hair breakage and occasional alopecia evident at
32 weeks (Fig 3, A, and see Fig E6, B). Scanning electron micro-
scopy confirmedMattma/ma and DM mice had fragile hairs prone
to longitudinal splitting and breakage with defective cuticle
morphology (see Fig E7, A, in this article’s Online Repository
at www.jacionline.org). Furthermore, Mattma/ma mice had dis-
torted hair follicle morphogenesis (see Fig E7, B).
FIG 1. Identification of Tmem79/Matt as the matted gene. A, A region of homozygous ma/ma on
chromosome 3 indicated by regions in red and heterozygous regions in blue, with the homozygous
C57BL6/J genome shown in black. B, The ma mutation in Tmem79/Matt identified by means of epidermal
transcriptome sequencing was confirmed by using Sanger sequencing, causing a C to G substitution at
position 88,136,485 on chromosome 3. This predicts the protein change p.Y280X in the Tmem79 (mattrin)
protein. The mutant allele was renamedMattma. C, Semiquantitative RT-PCR of epidermal mRNA showed a
reduction in expression of Matt in Mattma/ma animals. D, Mattrin detected in immunoblotting of skin from
WT and Flgft/ft mice but no protein expression in Mattma/ma and DM mice. E, Bioinformatics shows
mattrin consists of 5 transmembrane helices with a long intracellular N-terminus and short extracellular
C-terminus.
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have marked acanthosis (P < .001) and prominent orthokeratosis
(P < .001) with dermal inflammatory infiltrates (P < .001; see Fig
E5, B). In contrast, Flgft/ftmice had occasional foci of acanthosis,
mild diffuse orthokeratosis, and increased dermal cell infiltration
relative to WT mice (P <.001). However, the phenotype in Flgft/ft
mice was subclinical, with no overt dermatitis (Fig 3, A, and see
Fig E5, A).Mattma/ma mutant mice are atopic and have a
defective skin barrier
All mutant strains spontaneously had increased IgE levels
relative to WT mice, which was markedly more pronounced inMattma/ma and DM animals relative to Flgft/ft mice (P < .001; see
Fig E5, D). Because the severity of skin inflammation in AD par-
allels barrier permeability,27,28 TEWL was analyzed to quantify
skin barrier dysregulation in mouse strains. TEWL was signifi-
cantly increased in adult Mattma/ma and DM mice (P < .001; see
Fig E5, C). In contrast, TEWL was unaltered in Flgft/ft mice rela-
tive to that seen in WT animals (see Fig E5, C).
HDM allergen was applied to the intact skin of Mattma/ma and
WT mice to address whether the altered skin barrier inMattma/ma
mice influences allergen sensitization. Percutaneous sensitization
with allergen led to enhanced skin inflammation in Mattma/ma
mice (Fig 4, A-C). Consistent with the defective barrier, TEWL
was significantly upregulated (P < .001) in HDM-treated
Mattma/ma mice after allergen application (Fig 4, D). Crucially,
FIG 2. Mattrin expression and disorganized lipid morphology in the
epidermis of Mattma mice. A and B, Immunohistochemistry detection of
mattrin expression confined to the epidermal granular layer of WT (Fig 2,
A) but notMattma/ma (Fig 2, B) animals, including hair follicles (arrow). Scale
bar 5 20 mm. C and D, Nile Red staining of lipids in the epidermis of WT
(Fig 2, C) andMattma/ma (Fig 2, D) mice revealed uneven and highly disorga-
nized cornified cell envelopes in the stratum corneum of Mattma/ma mice.
Scale bar 5 50 mm.
FIG 3. Mattmamice are phenotypically distinct from Flgft/ftmice, with histo-
pathology demonstrating enhanced cutaneous inflammation at 32 weeks.
A, Gross phenotype of WT, DM, Mattma/ma, and Flgft/ft mice. Flgft/ft mice
are indistinguishable from WT mice, apart from the stubbed tail and short-
ened ear pinnae, which are phenotypic features shared with the DMmouse.
All mice are age-matched homozygous males. B, Representative skin
biopsy specimens from WT, DM, Mattma/ma, and Flgft/ft mice at 32
weeks, showing markedly increased cutaneous inflammation in DM and
Mattma/ma mice in comparison with that seen in WT and Flgft/ft mice.
Scale bar 5 50 mm.
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in the sera of HDM-treated Mattma/ma mice, as well as
HDM-specific IgG1 and IgG2a responses (Fig 4, E). In contrast,
the skin of WT (Fig 4) and Flgft/ft (data not shown) mice was
refractory to cutaneous HDM exposure. Collectively, these data
demonstrate that Mattma/ma mice have spontaneous AD and a
defective skin barrier that facilitates percutaneous allergic
sensitization.A mutation in MATT is associated with AD
To investigate whetherMATT is associated with human AD, all
exons of humanMATTwere sequenced in 55 Irish AD cases who
were negative for FLG null mutations. Several noncoding SNPs
and 1 known missense SNP, rs6684514, were identified (see
Table E2 in this article’s Online Repository at www.jacionline.
org). Case-control analyses conducted on 2 independent AD
case collections, English adult AD and United Kingdom pediatric
AD, with separate population-matched control subjects (see Table
E3) showed a significant association between rs6684514 and AD
(Table I). The minor allele (A) is protective for disease in both the
English adult AD (OR, approximately 0.791; P5 .0038) and UK
pediatric AD (OR, approximately 0.770; P 5 .0143) populations
(Table I). Notably, when controlling for the strong and significant
FLG null mutations, it was shown that the association of
rs6684514 with AD is independent of FLG (Table I and see
Table E4 in this article’s Online Repository at www.jacionline.
org). The association of rs6684514 with AD was further repli-
cated in a German AD case-control analysis in which the OR after
controlling for FLGmutations was 0.86 (95% CI, 0.76-0.97; P5
.0161; Table I). However, this association was not replicated in
Irish or Scottish case-control analyses (Table I). A meta-
analysis using a fixed-effects model of all 4,245 AD cases fromEngland, Scotland, Ireland, and Germany with 10,558
population-matched control subjects did not show significant het-
erogeneity between the study groups (P5 .078). A small but sig-
nificant effect of rs6684514 on AD risk was confirmed in the
meta-analysis (OR, 0.91; 95% CI, 0.86-0.96; P 5 .001; Fig 5;
see Table E4). A random-effects meta-analysis also produced
similar results (OR, 0.90; 95% CI, 0.82-0.98; P 5 .015; see Fig
E8 in this article’s Online Repository at www.jacionline.org).DISCUSSION
Previously, we demonstrated that FLG loss-of-function muta-
tions have a very strong relevance for the common inflammatory
skin disease AD and associated atopic phenotypes3,9,10 and iden-
tified an analogous mutation in the murine homolog Flg in the
spontaneously occurring flaky tail DM (maft) mouse.12 Subse-
quently, these DMmice have been widely used as a model of her-
itable skin barrier deficiency and spontaneous dermatitis13-15,17
and as a model of filaggrin deficiency–associated AD pathogen-
esis in patients.29 In this study we have identified the matted
phenotype in the DM mouse as arising from a second mutation
in Matt (Tmem79). The Mattma mutation results in defective
expression of the transmembrane protein mattrin, which is highly
expressed in the upper granular layer of epidermal keratinocytes,
with a predicted role in lipid homeostasis. These studies have
elucidated the relative contributions of the Flg and Matt muta-
tions in the DM mouse. The Mattma mutation led to the striking
development of spontaneous AD-like skin pathology and atopy
in adult mice. These data indicate that the DM mouse is not a
true model of filaggrin deficiency–associated AD-like skin
FIG 4. Mattmamice have exacerbated AD-like inflammation and HDM-specific responses after allergen chal-
lenge to intact skin. A, Representative skin biopsy specimens from age-matched WT and Mattma/ma mice
treated with HDM or vehicle, with increased inflammation in HDM-treated Mattma/ma mice relative to that
seen in HDM-treated WT and vehicle-treatedMattma/mamice. Scale bar5 50 mm. B, HDM treatment induces
increased dermal cell infiltration in Mattma/ma mice relative to that seen in HDM-treated WT and vehicle-
treated Mattma/ma mice. C, Acanthosis is increased in HDM-treated Mattma/ma mice relative to that seen in
HDM-treated WT and vehicle-treated Mattma/ma mice. D, Epicutaneous HDM treatment results in signifi-
cantly increased TEWL in Mattma/ma mice relative to that seen in HDM-treated WT mice. E, HDM-treated
Mattma/ma mice have increased HDM-specific serum IgE, IgG1, and IgG2 levels relative to those seen in
HDM-treated WT mice. Cell numbers and acanthosis were scored on 15 to 20 hpfs (31000 magnification)
on hematoxylin and eosin–stained sections from WT, DM, Mattma/ma, and Flgft/ft mice. Data represent the
mean and error bars represent 6 SEMs from 6 to 8 mice and are representative of 2 separate experiments.
The Student t test or 2-way ANOVA was used to determine statistical differences between groups. NS, Not
significant, *P > .05. ***P < .001.
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influence, whereas the Mattma mutation has a progressive influ-
ence with age. This indicates the polygenic nature of the DM
mouse as an AD model and indicates the differential influence
of both the Flgft and Mattma mutations. Recently, Flg2/2 mice
were shown to have no overt dermatitis with age,30 with the au-
thors unable to sensitize Flg2/2 mice by means of application
of OVA, an allergen commonly used in models of skin inflamma-
tion,31 to the intact skin barrier, results similar to our data.Notably, Flgft/ft mice were not sensitized to HDM (data not
shown), indicating an impermissibility of the Flgft/ft skin barrier
to protein antigen ingress. These data indicate that the DMmouse
is not a truemodel of filaggrin deficiency–associated AD-like skin
inflammation.
In this study we adopted a translational approach and also
addressed whether mattrin was implicated in human AD.
A missense SNP in MATTwas shown to have a small but signif-
icant effect on the risk for human AD. Because mattrin shows
TABLE I. Results of case-control analyses to investigate the association of rs6684514 and AD in 5 populations
Case-control comparison Cases (n)
Control
subjects (n)
P value for
rs6684514 OR 95% CI
P value for rs6684514
association after
controlling for
FLG null mutations
English adult severe AD vs English population control
subjects from the 1958 Birth Cohort
505 1919 .0038 0.791 0.674-0.929 .0008
UK mild-moderate pediatric AD vs English pediatric
control subjects without AD
338 538 .0153 0.770 0.622-0.953 .0328
Irish pediatric AD vs Irish adult population control subjects 724 1905 .1300 1.025 0.896-1.172 .7905
German AD cases vs German population control subjects 1543 2005 .0794 0.912 0.822-1.011 .0161
Scottish asthma cases with AD vs Scottish population
control subjects
1135 4189 .1365 0.922 0.831-1.023 NA
English adult severe AD is defined as early-onset, persistent, and severe disease. UK mild-moderate pediatric AD includes cases collected from an English population birth cohort
(n5 177) and a Scottish General Practice collection (n5 161); the English pediatric control subjects were ascertained not to have AD at the age of 7 to 9 years. Irish pediatric AD
cases were collected in secondary and tertiary care clinics in Ireland; Irish population control subjects are healthy adult blood donors. Scottish asthma cases with AD are subjects
with physician-diagnosed asthma and parent-reported AD. The German case and control rs6684514 genotypes were ascertained by imputation from genome-wide SNP analysis
data; all other SNP genotypes and FLG null mutations were analyzed by using TaqMan allelic discrimination assays. In the English, United Kingdom, and Irish collections, 4
prevalent FLG null mutations were analyzed (R501X, 2282del4, R2447X, and S3247X), whereas in the German population 2 FLG null mutations were analyzed (R501X and
2282del4). Statistical analysis was performed through logistic regression in Stata 10.0 software (StataCorp).
NA, FLG genotype data not available.
FIG 5. Forrest plot showing results of a fixed-effects meta-analysis of 5 case-control studies to investigate
the association of rs6684514 and AD. Study populations used were as follows: English, English adult severe
AD versus English population control subjects from the 1958 Birth Cohort; UK, UK mild-moderate pediatric
AD versus English pediatric control subjects without AD; Irish, Irish pediatric AD versus Irish adult popula-
tion controls; German, German AD cases versus German population control subjects; Scottish, Scottish
asthma cases with AD versus Scottish population control subjects. ES, Estimated odds ratio. Meta-
analysis was carried out with the ‘‘metan’’ function in Stata software (StataCorp).
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are known to catalyze glutathione-dependent transformations of
lipophilic substrates at the lipid bilayer, sequence homology sug-
gests a possible role for mattrin in the biology of lipids or lipid-
like molecules.25 Epidermal transcriptomic analysis of WT
versusMattma/mamice has revealed changes in several transcripts
involved in fatty acid and lipid biology (data not shown). Howev-
er, 1-dimensional and 2-dimensional thin-layer chromatography
of epidermal lipid extracts did not reveal any differences in the
migration or abundance of ceramides, phospholipids, or polar
or nonpolar lipids between WT and Mattma/ma mice (data not
shown). Future work will require analysis of the glutathionebinding of mattrin, elucidation of lipophilic substrates of mattrin,
and an investigation of the downstream signaling pathways and
local immunologic milieu in Mattma mice.
In summary, using a translational mouse-patient strategy, we
have identified a new gene mutation that leads to dermatitis in
mice and have further demonstrated that a variant in the human
gene is associated with AD.
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bility to AD and related allergic conditions should be further
investigated.
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